Real-life management of patients with breakthrough cancer pain caused by bone metastases in Spain
Por:
Albiach C, Estevez F, Alarcon M, de Madariaga M, Carregal A, Arranz J, Martin-Arroyo J, Lopez A, Yague A
Publicada:
1 ene 2019
Resumen:
Purpose: We aimed to explore the characteristics, and real-life therapeutic management of patients with breakthrough cancer pain (BTcP) caused by bone metastases in Spain, and to evaluate physicians' opinion of and satisfaction with prescribed BTcP therapy.
Participants and methods: For the purposes of this study, an ad-hoc questionnaire was developed consisting of two domains: a) organizational aspects and care standards; b) clinical and treatment variables of bone metastatic BTcP patients. In addition, physicians' satisfaction with their prescribed BTcP therapy was assessed. Specialists collected data from up to five patients receiving treatment for BTcP caused by bone metastasis, all patients gave their consent to participate prior to inclusion.
Results: A total of 103 cancer pain specialists (radiation oncologists [38.8%], pain specialists [33.0%], and palliative care (PC) specialists [21.4%]) were polled, and data on 386 BTcP patients with bone metastatic disease were collected. Only 33% of the specialists had implemented specific protocols for BTcP management, and 19.4% had established referral protocols for this group of patients. Half of all participants (50.5%) address quality of life and quality of care in their patients; however, only 27.0% did so from the patient's perspective, as they should do. Most patients had multiple metastases and were prescribed rapid-onset fentanyl preparations (71.2%), followed by immediate-release morphine (9.3%) for the treatment of BTcP. Rapid-onset fentanyl was prescribed more often in PC units (79.0%) than in pain units (75.9%) and radiation oncology units (61.1%) (p<0.01). Furthermore, most physicians (71.8%) were satisfied with the BTcP therapy prescribed.
Conclusions: Our results demonstrate the need for routine assessment of quality of life in patients with bone BTcP. These findings also underscore the necessity for a multidisciplinary therapeutic strategy for breakthrough pain in clinical practice in Spain.
Filiaciones:
Albiach C:
Consorcio Hosp Prov Castellon, Dept Radiat Oncol, Castellon de La Plana, Spain
Estevez F:
Consorcio Hosp Prov Castellon, Pain Unit, Castellon de La Plana, Spain
Alarcon M:
Hosp Gen Univ Valencia, Pain Unit, Valencia, Spain
de Madariaga M:
Hosp Univ Infanta Sofia, Pain Unit, Madrid, Spain
Carregal A:
Complexo Hosp Univ Vigo CHUVI, Pain Unit, Pontevedra, Spain
Arranz J:
Hosp Univ Nuestra Senora Candelaria, Pain Unit, Tenerife, Spain
Martin-Arroyo J:
Hosp Puerta del Mar, Pain Unit, Cadiz, Spain
Lopez A:
SLU, Kyowa Kirin Farmaceut, Dept Med, Madrid, Spain
Yague A:
SLU, Kyowa Kirin Farmaceut, Dept Med, Madrid, Spain
|